Johnson & Johnson (J&J) has been making significant changes in recent years. The company has been focusing more on pharmaceuticals and medical devices. In 2023, J&J sold its consumer health division, which is now a separate company called Kenvue. This sale provided funds for innovation in pharmaceuticals and medical technology. Recently, J&J announced it will also separate its orthopedics unit, which makes hip and knee replacements and other devices. This unit will operate under the name DePuy Synthes. After these changes, J&J will have more resources dedicated to developing new medicines, particularly in cancer, immune system disorders, and brain-related conditions. J&J’s CEO, Joaquin Duato, stated that these changes will help the company grow faster. Cancer treatments are currently J&J’s biggest sellers. Darzalex, a medicine for a type of blood cancer called multiple myeloma, is a major success. Another promising treatment is Carvykti, a cell therapy for multiple myeloma that has shown significant growth. J&J also has new medicines in development, like Inlexzo for bladder cancer and icatrekibart for a skin condition called plaque psoriasis. In immunology, J&J faces challenges as its blockbuster drug Stelara faces competition. However, another drug called Tremfya is quickly gaining ground. In neuroscience, J&J’s presence is growing with drugs like Spravato for depression and Caplyta for schizophrenia and bipolar disorder. These changes and new treatments show J&J’s commitment to improving health care through innovation.